CNTB Revenue second quarter 2026 Y/Y Growth Comment
Connect Biopharma Holdings Limited achieved in the second quarter 2026, above Company average Revenue surge of 5436% year on year, to $ 2.77 millions.
Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 4 other companies have achieved higher Revenue growth. While Connect Biopharma Holdings Limited' s Revenue doubling of 5436% ranks overall at the positon no. 20 in the second quarter 2026.
Connect Biopharma Holdings Limited achieved in the II. Quarter 2026 above company average sequential Revenue doubling of 1528.24%, to $ 2.77 millions, from $0.17 millions in the first quarter. CNTB is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.
Within Major Pharmaceutical Preparations industry 6 other companies have achieved higher Revenue quarter on quarter growth. While Connect Biopharma Holdings Limited's Revenue growth quarter on quarter, overall rank is 24.
Connect Biopharma Holdings Limited achieved in the II. Quarter 2026 above company average sequential Revenue doubling of 1528.24%, to $ 2.77 millions, from $0.17 millions in the first quarter. CNTB is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.
Within Major Pharmaceutical Preparations industry 6 other companies have achieved higher Revenue quarter on quarter growth. While Connect Biopharma Holdings Limited's Revenue growth quarter on quarter, overall rank is 24.
Connect Biopharma Holdings Limited's 12 Months Revenue Growth Year on Year
In the Jun 30 2026 period, Connect Biopharma Holdings Limited's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.
Connect Biopharma Holdings Limited achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .
In the Jun 30 2026 period, Connect Biopharma Holdings Limited's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.
Connect Biopharma Holdings Limited achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .
About Connect Biopharma Holdings Limited Revenue Growth Rates (CNTB), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
8,608.59%